Coronary microvascular disease: The "Meeting Point" of Cardiology, Rheumatology and Endocrinology.
George Markousis-MavrogenisFlora BacopoulouClio MavraganiParaskevi VoulgariGenovefa KolovouGeorge D KitasGeorge P ChrousosSophie I MavrogeniPublished in: European journal of clinical investigation (2022)
CMD is a multifactorial disease leading to myocardial ischemia/fibrosis alone or in combination with epicardial coronary artery disease. Endothelial dysfunction/vasospasm, systemic inflammation, and/or neuroendocrine activation may act as causative factors and bring Cardiology, Rheumatology and Endocrinology together. Currently, the application of advanced imaging modalities, and specifically CMR, allows reliable assessment of the extent and severity of CMD. These measurements should not be limited to "pure cardiac patients", as it is known that CMD affects the majority of patients with autoimmune rheumatic and endocrine/metabolic disorders.
Keyphrases
- coronary artery disease
- end stage renal disease
- left ventricular
- chronic kidney disease
- newly diagnosed
- ejection fraction
- cardiac surgery
- juvenile idiopathic arthritis
- rheumatoid arthritis
- coronary artery
- subarachnoid hemorrhage
- prognostic factors
- percutaneous coronary intervention
- peritoneal dialysis
- cardiovascular events
- heart failure
- coronary artery bypass grafting
- acute kidney injury
- aortic stenosis
- systemic lupus erythematosus
- blood brain barrier
- patient reported
- disease activity
- cerebral ischemia